Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference

FREMONT, Calif., Feb. 27, 2017

To access the live webcast of Ardelyx's presentation, please visit the Events & Presentations page within the Investor page of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 30 days following the conference.

About Ardelyx, Inc.

Ardelyx is focused on enhancing the way patients with cardiorenal and gastrointestinal (GI) diseases are treated by using the gut as the gateway to delivering medicines that matter. The company has established unique cardiorenal and GI business units aimed at bringing new, effective medicines with distinct safety and dosing advantages to underserved patients. Ardelyx's cardiorenal portfolio includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and the Phase 3 development of RDX7675 for the treatment of people with hyperkalemia. The company's GI portfolio includes the Phase 3 development of tenapanor for the treatment of people with irritable bowel syndrome with constipation (IBS-C), and RDX8940, a TGR5 agonist approaching Phase 1 development. Leveraging the company's platform and unique gut-restriction chemistry, Ardelyx intends to build a fully integrated, revenue-generating biopharmaceutical company with leading cardiorenal and GI business units. For more information, please visit www.ardelyx.com and connect with us on Twitter @Ardelyx.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ardelyx-announces-presentation-at-cowen-and-company-37th-annual-healthcare-conference-300414210.html